ArticleJournal of cheminformatics2026
ChemScreener: an active learning enabled hit discovery workflow with WDR5 inhibitor case study.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active deep learning offers a promising approach for hit discovery starting from limited data by iteratively updating and improving models during screening by applying new data and adapting decisions. Key open questions include how best to explore chemical space, how it compares to non-iterative methods, and how to use it under data scarcity. We present ChemScreener, a multi-task active learning workflow for early drug discovery across large, diverse libraries or chemical spaces. Its Balanced-Ranking acquisition strategy leverages ensemble uncertainty to explore novel chemistry while maintaining hit rate enrichment by prioritizing predicted activity. In five iterative single-dose HTRF screens on WDR5 protein, ChemScreener increased hit rates from 0.49% (primary HTS screen) to 3-10% (average 5.91%; 104 hits from 1760 compounds). Hits were consolidated, retested with close analogs together in the 269 compounds set and clustered; 44 hit compounds from 81 clusters of 269 compounds set advanced to dose-response and filtered by counter HTRF assays. Over 50% of those with IC50 < 45 μM were validated as WDR5 binders by DSF. We de novo identified three scaffold series and three singleton scaffolds as the hits. Overall, we demonstrated that ChemScreener can accelerate early hit discovery and yield more diverse chemotypes.Scientific contributionHit identification is a costly, time-intensive stage in drug discovery. We developed ChemScreener, a scalable active learning workflow for early hit discovery that improves hit rate enrichment through iterative screening of small number of compounds and expands chemical diversity by de novo hit scaffolds identified. ChemScreener offers a generalizable, target-specific, ligand-based virtual screening framework that accelerates early discovery and enhances effectiveness across large, diverse chemical libraries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.